How to Choose a Food Bolus IV Glucagon: Key Product Attributes Guide
Abstract: Selecting a food bolus IV glucagon requires evaluating peptide purity (>98%), stability, and regulatory compliance (FDA/EMA). Market trends show 8.2% CAGR (2024–2030) driven by diabetes and hypoglycemia management. Leading brands (Novo Nordisk, Eli Lilly) dominate with recombinant DNA technology, offering superior bioavailability vs. synthetic analogs. Key attributes include excipient composition (e.g., lactose-free), cold-chain logistics (2–8°C), and GMP-certified facilities. Comparative analysis highlights trade-offs: synthetic peptides enable cost efficiency but risk immunogenicity; recombinant ensures safety. Certifications (ISO 13485, cGMP) are critical. For procurement, prioritize batch consistency, stability data, and supplier audits.